These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6136015)

  • 1. Behavioral effects of melanocyte stimulating hormone release-inhibiting factor-1 (MIF-1).
    von Almen TK; Olson GA; Olson RD
    Neurosci Biobehav Rev; 1983; 7(2):257-62. PubMed ID: 6136015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Central action of melanostatin and the opiate system of the brain].
    Chepurnova NE; Klusha VE; Borzenkov VM; Lapishin DN; Khatskelevich AIa
    Fiziol Zh SSSR Im I M Sechenova; 1985 Aug; 71(8):937-44. PubMed ID: 2865175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSH and MIF-I in animal models of tardive dyskinesia.
    Davis KL; Kastin AJ; Beilstein BA; Vento AL
    Pharmacol Biochem Behav; 1980 Jul; 13(1):37-40. PubMed ID: 6105677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
    Pugsley TA; Lippmann W
    Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocyte-stimulating hormone release-inhibiting factor (MIF): lack of dopaminergic and anticholinergic activity.
    Carolei A; Margotta V; Palladini G
    Neuroendocrinology; 1977; 23(3):129-32. PubMed ID: 19714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-Leu-Gly-NH2 serves as a conditioned stimulus in the acquisition of conditioned tolerance.
    McLaughlin CR; Lichtman AH; Fanselow MS; Cramer CP
    Behav Neurosci; 1989 Apr; 103(2):447-51. PubMed ID: 2565116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with MIF-1 prevents the painful stimuli threshold elevation induced by neonatal handling in mice.
    d'Amore A; Pieretti S; Chiarotti F; Loizzo A
    Peptides; 1991; 12(6):1291-4. PubMed ID: 1687709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys.
    Crowley TJ; Hydinger M
    Psychopharmacology (Berl); 1977 Jul; 53(2):205-6. PubMed ID: 19803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of alpha-MSH and MIF-I with amphetamine on open-field behavior of rats.
    Sandman CA; Kastin AJ
    Pharmacol Biochem Behav; 1978 Dec; 9(6):759-62. PubMed ID: 34173
    [No Abstract]   [Full Text] [Related]  

  • 11. Opiate receptor antagonism by L-prolyl-L-leucyl-glycinamide, MIF-I.
    Dickinson SL; Slater P
    Peptides; 1980; 1(4):293-9. PubMed ID: 6117839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
    Cox B; Kastin AJ; Schnieden H
    Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental, behavioral, and opiate receptor changes after prenatal or postnatal beta-endorphin, CRF, or Tyr-MIF-1.
    Zadina JE; Kastin AJ; Coy DH; Adinoff BA
    Psychoneuroendocrinology; 1985; 10(4):367-83. PubMed ID: 2868478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of MIF-1 or naloxone to reverse ischemic-induced neurologic deficits in gerbils.
    Kastin AJ; Nissen C; Olson RD
    Pharmacol Biochem Behav; 1982 Nov; 17(5):1083-5. PubMed ID: 6129645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of prolyl-leucyl-glycinamide on behavioral and visceral functions in dogs].
    Pastukhov VA; Lozhkina TK
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1990; 40(2):372-3. PubMed ID: 1974376
    [No Abstract]   [Full Text] [Related]  

  • 17. Alpha-MSH and MIF-I effects on catecholamine levels and synthesis in various rat brain areas.
    Kostrzewa RM; Kastin AJ; Spirtes MA
    Pharmacol Biochem Behav; 1975; 3(6):1017-23. PubMed ID: 4815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1.
    Galina ZH; Kastin AJ
    Life Sci; 1986 Dec; 39(23):2153-9. PubMed ID: 2878336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of melanostatin on the central nervous system].
    Chepurnova NE; Borzenkov VM; Chepurnov SA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of neonatal treatment with Tyr-MIF-1, morphiceptin, and morphine on development, tail flick, and blood-brain barrier transport.
    Harrison LM; Zadina JE; Banks WA; Kastin AJ
    Brain Res Dev Brain Res; 1993 Oct; 75(2):207-12. PubMed ID: 7903224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.